阿托伐他汀联合单硝酸异山梨酯治疗冠心病心绞痛的临床研究

目的观察阿托伐他汀联合单硝酸异山梨酯治疗冠心病心绞痛的临床疗效。方法选取2015年7月—2016年6月平煤神马医疗集团总医院收治的106例冠心病心绞痛患者,随机分为对照组和治疗组,每组各53例。对照组口服单硝酸异山梨酯片,20 mg/次,2次/d;治疗组在对照组的基础上睡前口服阿托伐他汀钙片,20 mg/次,1次/d。两组患者均连续治疗4周。比较两组患者治疗前后临床疗效、临床症状和心电图改善情况,同时评价三酰甘油(TG)、胆固醇(CHO)、低密度脂蛋白(LDL-C)水平、高敏C反应蛋白(hs-CRP)和白细胞介素-6(IL-6)水平。结果治疗后,对照组和治疗组总有效率分别为69.81%、88.68%,两组总有效率比较差异有统计学意义(P0.05)。治疗后,对照组心电图改善总有效率为67.92%,显著低于治疗组的86.79%,两组患者心电图改善情况比较差异具有统计学意义(P0.05)。治疗后,两组心绞痛发作次数和持续时间均显著下降,同组治疗前后比较差异具有统计学意义(P0.05);且治疗后治疗组患者临床症状改善情况优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组TG、CHO、LDL-C血脂水平、hs-CRP和IL-6水平均显著降低(P0.05);且治疗组这些指标降低水平优于对照组,两组比较差异具有统计学意义(P0.05)。结论阿托伐他汀联合单硝酸异山梨酯治疗冠心病心绞痛效果显著,可有效改善临床症状、血脂水平和炎性反应,具有一定的临床推广应用价值。

Clinical study on atorvastatin combined with isosorbide mononitrate in treatment of coronary heart disease with angina pectoris

Objective To observe the clinical efficacy of atorvastatin combined with isosorbide mononitrate in treatment of coronary heart disease with angina pectoris. Methods Patients (106 cases) with coronary heart disease with angina pectoris in Pingmei Shenma Medical Group General Hospital from July 2015 to June 2016 were randomly divided into control and treatment groups, and each group had 53 cases. Patients in the control group were po administered with Isosorbide Mononitrate Tablets, 20 mg/time, twice daily. Patients in the treatment group were po administered with Atorvastatin Calcium Tablets on the basis of the control group, 20 mg/time, once daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy, clinical symptoms and electrocardiogram in two groups before and after treatment were compared, and the levels of TG, CHO, LDL-C, hs-CRP, and IL-6 in two groups were evaluated. Results After treatment, the clinical efficacies in the control and treatment groups were 69.81% and 88.68%, respectively, and there was difference between two groups (P<0.05). After treatment, the frequency and duration of angina pectoris in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the clinical symptoms in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the improvement rate of electrocardiogram in the control was 67.92%, which was significantly lower than 86.79% in the treatment group, and there was difference between two groups (P<0.05). After treatment, TG, CHO, LDL-C, hs-CRP, and IL-6 levels in two groups were significantly decreased (P<0.05). And these indicators in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Atorvastatin combined with isosorbide mononitrate has significant clinical effect in treatment of coronary heart disease with angina pectoris, can effectively improve the clinical symptoms, inflammatory response, and blood lipid levels, which has a certain clinical application value.